International Conference on Oncolytic Virus Therapeutics (ICOVT )
In Association With
International Conference on Oncolytic Virus Therapeutics(ICOVT) on 30th Dec-31st Dec 2022 At Beijing,China.
"Since the spread of COVID-19 is getting serious worldwide, we'd like to inform you that the conference organizing committee has decided to convert the event to online meeting in order to ensure the safety and health of all the participants".
International Conference on Oncolytic Virus Therapeutics(ICOVT)
aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Oncolytic Viruses and Immunotherapy. It also provides a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of Oncolytic Viruses and Immunotherapy. Oncolytic Virus is an international platform for presenting research about Virus Outbreaks, control and Therapy. It represents an increasingly important cause of human morbidity and mortality throughout the world. Vaccine development is thus of great importance in terms of global health. Oncolytic viruses are a novel class of anti-cancer agents which in many cases have entered clinical trials. These viruses are capable of attacking cancer cells in a distinctive manner leading to cell-specific and targeted tumor therapy.
Benefits of attending online
CONNECT IN REAL TIME
Connect, inform and support each other in real time as an online community during this period of physical distancing.
Watch live and learn from the comfort of your home or office on your phone, mobile device and/or computer.
ACCESS TO CONTENT
Access recordings of all topics to view at your convenience after the conference. Experience all topics over and over again.
Call For Paper ICOVT
Oncolytic Virus Therapeutics
Oncolytic Virus-Based Immunotherapies
Oncolytic Virotherapy for Hematological Malignancies